The chemical substance with the name "(4S)-6-(4-Chlorophenyl)-1-methyl-4-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-4H-[1,2,4]triazolo[4,3-a][1]benzazepine" and CAS number "2070009-49-1" is a complex organic compound characterized by its multi-ring structure, which includes a benzazepine core fused with a triazole and an oxadiazole moiety. The presence of a chlorophenyl group suggests potential interactions with biological targets, making it of interest in medicinal chemistry. The specific stereochemistry indicated by the (4S) configuration implies that the compound has a defined three-dimensional arrangement, which can significantly influence its pharmacological properties. Additionally, the methyl and oxadiazole substituents may contribute to its solubility and reactivity. Such compounds are often investigated for their potential therapeutic applications, particularly in areas like neuropharmacology or oncology, due to their ability to modulate various biological pathways. Understanding the characteristics of this compound requires further studies on its synthesis, stability, and biological activity.

(4S)-6-(4-Chlorophenyl)-1-methyl-4-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-4H-[1,2,4]triazolo[4,3-a][1]benzazepine

2070009-49-1: The chemical substance with the name "(4S)-6-(4-Chlorophenyl)-1-methyl-4-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-4H-[1,2,4]triazolo[4,3-a][1]benzazepine" and CAS number "2070009-49-1" is a complex organic compound characterized by its multi-ring structure, which includes a benzazepine core fused with a triazole and an oxadiazole moiety. The presence of a chlorophenyl group suggests potential interactions with biological targets, making it of interest in medicinal chemistry. The specific stereochemistry indicated by the (4S) configuration implies that the compound has a defined three-dimensional arrangement, which can significantly influence its pharmacological properties. Additionally, the methyl and oxadiazole substituents may contribute to its solubility and reactivity. Such compounds are often investigated for their potential therapeutic applications, particularly in areas like neuropharmacology or oncology, due to their ability to modulate various biological pathways. Understanding the characteristics of this compound requires further studies on its synthesis, stability, and biological activity.

<p>The S-enantiomer of BET-BAY 002, referred to as BET-BAY 002 S enantiomer, is a potent inhibitor of BET (Bromodomain and Extra-Terminal motif proteins).</p>

CAS 2070009-49-1

(4S)-6-(4-Chlorophenyl)-1-methyl-4-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-4H-[1,2,4]triazolo[4,3-a][1]benzazepine

BET-BAY 002 (S enantiomer)

Ref: TM-T10517